TfR-1-IN-1

TfR-1-IN-1 (C4) (0.1-10 μM; 72 h) potently reduces the metabolic activity of MDA-MB 231, HL-60 and A2780cis tumor cells, with IC₅₀ values of 0.46, 0.48 and 0.51 μM, respectively; it also exhibits tumor cell specificity at a concentration of 0.5 μM and shows no effect on non-malignant HS-5 cells^[1].
TfR-1-IN-1 (1 μM; 2-24 h) increases intracellular iron levels in MDA-MB 231 cells, with the level rising from 69.7 pg Fe/μg protein at 12 h to 86.0 pg Fe/μg protein at 24 h^[1].
TfR-1-IN-1 (0.1-1 μM; 12-24 h) downregulates TfR-1 expression in MDA-MB 231 cells in a concentration- and time-dependent manner^[1].
TfR-1-IN-1 (1 μM; 4-20 h) significantly increases the labile iron ²⁺ pool in MDA-MB 231 cells within 4 h, while ferristatin II-mediated inhibition of TfR-1 partially attenuates this effect^[1].
TfR-1-IN-1 (0.1-0.5 μM; 24 h) reduces the mitochondrial membrane potential of MDA-MB 231 cells in a concentration-dependent manner, and treatment with 0.5 μM for 24 h decreases ΔΨm to 57.3% of that in the control group^[1].
TfR-1-IN-1 (1 μM; 24 h) induces cell death in MDA-MB 231 cells, with apoptotic death accounting for 25.9% and non-apoptotic death accounting for 49.8%^[1].
TfR-1-IN-1 (0.1-1 μM; 2-4 h) induces concentration-dependent lipid peroxidation in MDA-MB 231 cells, with a peroxidation level of 3.5% observed after treatment with 1 μM for 4 h, whereas non-malignant HS-5 cells show only an extremely weak response^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.